These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2228838)

  • 41. An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins.
    Smyth ET; Barr JG; O'Neill CA; Hogg GM
    Pharmacoeconomics; 1995 Dec; 8(6):541-50. PubMed ID: 10160082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Fundamental study of ceftriaxone in the field of obstetrics and gynecology].
    Itoh K; Kondoh H; Hayasaki M; Noda K
    Jpn J Antibiot; 1984 Dec; 37(12):2343-8. PubMed ID: 6098727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study on tissue transfer of ceftriaxone in the field of obstetrics and gynecology].
    Matsui Y; Noda M; Kohara T
    Jpn J Antibiot; 1984 Dec; 37(12):2320-7. PubMed ID: 6098724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and dosage regimen of cefotaxime in cross-bred calves following single intramuscular administration.
    Sharma SK; Srivastava AK
    Vet Res Commun; 1994; 18(4):313-8. PubMed ID: 7831762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of cefotaxime and ceftriaxone on the bowel and vaginal flora after single-dose prophylaxis in vaginal hysterectomy.
    Bräutigam HH; Knothe H; Rangoonwala R
    Drugs; 1988; 35 Suppl 2():163-8. PubMed ID: 3135167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetics and clinical studies on ceftriaxone in the field of obstetrics and gynecology].
    Cho N; Watanabe H; Yoshida K; Moriyama S; Takeda H; Tsukamoto A; Fukunaga K; Kunii K; Komoriyama Y
    Jpn J Antibiot; 1984 Dec; 37(12):2304-19. PubMed ID: 6098723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone.
    Lovering AM; Walsh TR; Bannister GC; MacGowan AP
    J Antimicrob Chemother; 2001 Apr; 47(4):483-6. PubMed ID: 11266427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Penetration of third-generation cephalosporins into human peritoneal tissue.
    Berger SA; Dan M; Serour F; Gorea A; Levenberg A; Krispin M
    Chemotherapy; 1989; 35(5):326-9. PubMed ID: 2676403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Dec; 48(6):748-752. PubMed ID: 27838278
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Penetration of cefotaxime into bronchial secretions.
    Bergogne-Berezin E; Morel C; Pierre J; Monrocq N; Dournovo P; Benard Y
    Rev Infect Dis; 1982; 4 Suppl():S392-5. PubMed ID: 6294788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PKQuest: capillary permeability limitation and plasma protein binding - application to human inulin, dicloxacillin and ceftriaxone pharmacokinetics.
    Levitt DG
    BMC Clin Pharmacol; 2002 Sep; 2():7. PubMed ID: 12323078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetics and tissue penetration of ceftriaxone].
    Bergan T
    Rev Med Interne; 1985 Mar; 6(2):163-77. PubMed ID: 3890053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concentrations of ceftriaxone in prostate adenoma tissue.
    Adam D; Naber KG
    Chemotherapy; 1984; 30(1):1-6. PubMed ID: 6198127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients.
    Schleibinger M; Steinbach CL; Töpper C; Kratzer A; Liebchen U; Kees F; Salzberger B; Kees MG
    Br J Clin Pharmacol; 2015 Sep; 80(3):525-33. PubMed ID: 25808018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
    Stoeckel K; Koup JR
    Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Fundamental and clinical studies on ceftriaxone in the field of obstetrics and gynecology].
    Sakakura K; Hayashi S
    Jpn J Antibiot; 1984 Dec; 37(12):2328-37. PubMed ID: 6098725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cefotaxime and ceftriaxone levels in pancreas tissue and pancreatic juice.
    Pulay I; Arr M; Bryskier A; Flautner L; Tihanyi T; Magyar A
    J Chemother; 1989 Jul; 1(4 Suppl):527-8. PubMed ID: 16312516
    [No Abstract]   [Full Text] [Related]  

  • 59. The acute-phase proteins serum amyloid A and C reactive protein in transudates and exudates.
    Okino AM; Bürger C; Cardoso JR; Lavado EL; Lotufo PA; Campa A
    Mediators Inflamm; 2006; 2006(1):47297. PubMed ID: 16864904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis.
    Losno Garcia R; Santivañez V; Battilana CA
    Chemotherapy; 1988; 34(4):261-6. PubMed ID: 3208543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.